• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 SELEX 的针对 SARS-CoV-2 的诊断和进入抑制剂治疗性适配子。

SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2.

机构信息

Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.

Department of Chemistry, University of Miami, Coral Gables, FL, 33146, USA.

出版信息

Sci Rep. 2023 Sep 4;13(1):14560. doi: 10.1038/s41598-023-41885-w.

DOI:10.1038/s41598-023-41885-w
PMID:37666993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10477244/
Abstract

Frequent mutation and variable immunological protection against vaccination is a common feature for COVID-19 pandemic. Early detection and confinement remain key to controlling further spread of infection. In response, we have developed an aptamer-based system that possesses both diagnostic and therapeutic potential towards the virus. A random aptamer library (~ 10 molecules) was screened using systematic evolution of ligands by exponential enrichment (SELEX) and aptamer R was identified as a potent binder for the SARS-CoV-2 spike receptor binding domain (RBD) using in vitro binding assay. Using a pseudotyped viral entry assay we have shown that aptamer R specifically inhibited the entry of a SARS-CoV-2 pseudotyped virus in HEK293T-ACE2 cells but did not inhibit the entry of a Vesicular Stomatitis Virus (VSV) glycoprotein (G) pseudotyped virus, hence establishing its specificity towards SARS-CoV-2 spike protein. The antiviral potential of aptamers R and J (same central sequence as R but lacking flanked primer regions) was tested and showed 95.4% and 82.5% inhibition, respectively, against the SARS-CoV-2 virus. Finally, intermolecular interactions between the aptamers and the RBD domain were analyzed using in silico docking and molecular dynamics simulations that provided additional insight into the binding and inhibitory action of aptamers R and J.

摘要

频繁的突变和针对疫苗接种的可变免疫保护是 COVID-19 大流行的共同特征。早期检测和隔离仍然是控制感染进一步传播的关键。有鉴于此,我们开发了一种基于适体的系统,该系统具有针对该病毒的诊断和治疗潜力。使用指数富集的配体系统进化(SELEX)筛选了一个随机适体文库(约 10 个分子),并通过体外结合试验鉴定出适体 R 是 SARS-CoV-2 刺突受体结合域(RBD)的有效结合物。使用假型病毒进入试验,我们已经表明适体 R 特异性抑制了 SARS-CoV-2 假型病毒在 HEK293T-ACE2 细胞中的进入,但不抑制水疱性口炎病毒(VSV)糖蛋白(G)假型病毒的进入,因此确立了其对 SARS-CoV-2 刺突蛋白的特异性。测试了适体 R 和 J(与 R 具有相同的中心序列但缺少侧翼引物区域)的抗病毒潜力,发现它们对 SARS-CoV-2 病毒的抑制率分别为 95.4%和 82.5%。最后,使用计算对接和分子动力学模拟分析了适体与 RBD 结构域之间的分子间相互作用,这为适体 R 和 J 的结合和抑制作用提供了更多的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/f17ab36a8408/41598_2023_41885_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/b837de404748/41598_2023_41885_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/a21ca57d93ee/41598_2023_41885_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/3cd45fc76f7f/41598_2023_41885_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/ac4ea6b1407f/41598_2023_41885_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/fb9041f9d887/41598_2023_41885_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/a6c18a148016/41598_2023_41885_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/748c6ea7c930/41598_2023_41885_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/0ef89f53ac6e/41598_2023_41885_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/8f4322e045e4/41598_2023_41885_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/ed606fd6dc39/41598_2023_41885_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/f17ab36a8408/41598_2023_41885_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/b837de404748/41598_2023_41885_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/a21ca57d93ee/41598_2023_41885_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/3cd45fc76f7f/41598_2023_41885_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/ac4ea6b1407f/41598_2023_41885_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/fb9041f9d887/41598_2023_41885_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/a6c18a148016/41598_2023_41885_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/748c6ea7c930/41598_2023_41885_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/0ef89f53ac6e/41598_2023_41885_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/8f4322e045e4/41598_2023_41885_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/ed606fd6dc39/41598_2023_41885_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/10477244/f17ab36a8408/41598_2023_41885_Fig11_HTML.jpg

相似文献

1
SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2.基于 SELEX 的针对 SARS-CoV-2 的诊断和进入抑制剂治疗性适配子。
Sci Rep. 2023 Sep 4;13(1):14560. doi: 10.1038/s41598-023-41885-w.
2
DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach.DNA 适体通过非 RBD 依赖或依赖的方式抑制 SARS-CoV-2 刺突蛋白与 hACE2 的结合。
Theranostics. 2022 Jul 18;12(12):5522-5536. doi: 10.7150/thno.74428. eCollection 2022.
3
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.一种新的 DNA 适体可与 SARS-CoV-2 刺突蛋白结合并减少促炎反应。
Sci Rep. 2024 Mar 29;14(1):7516. doi: 10.1038/s41598-024-58315-0.
4
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.基于 ACE2 受体或工程化 Spike 结合肽的 SARS-CoV-2 进入抑制剂比较。
J Virol. 2023 Aug 31;97(8):e0068423. doi: 10.1128/jvi.00684-23. Epub 2023 Aug 9.
5
selection of a single-strand DNA aptamer targeting the receptor-binding domain of SARS-CoV-2 spike protein.筛选靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域的单链DNA适配体。
Nucleosides Nucleotides Nucleic Acids. 2023;42(2):105-118. doi: 10.1080/15257770.2022.2109170. Epub 2022 Aug 10.
6
DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic.DNA 适体掩蔽血管紧张素转化酶 2 作为治疗 SARS-CoV-2 大流行的创新方法。
Pharmacol Res. 2022 Jan;175:105982. doi: 10.1016/j.phrs.2021.105982. Epub 2021 Nov 16.
7
In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.基于计算机的 SARS-CoV-2 刺突蛋白适配体靶标选择。
Int J Mol Sci. 2022 May 22;23(10):5810. doi: 10.3390/ijms23105810.
8
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.SARS-COV-2 刺突糖蛋白的优化假型条件。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01062-20.
9
Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.异核酸(XNA)2'-氟阿拉伯糖核酸(FANA)适体与 SARS-CoV-2 S 蛋白受体结合域结合,阻断 ACE2 结合。
Viruses. 2021 Oct 2;13(10):1983. doi: 10.3390/v13101983.
10
, and Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion.用于监测 SARS-CoV-2 刺突/人 ACE2 复合物、病毒进入和细胞融合的模型。
Viruses. 2021 Feb 25;13(3):365. doi: 10.3390/v13030365.

引用本文的文献

1
Aptamer Development for SARS-CoV-2 and Omicron Variants Using the Spike Protein Receptor Binding Domain as a Potential Diagnostic Tool and Therapeutic Agent.利用刺突蛋白受体结合域开发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其奥密克戎变种的适配体,作为一种潜在的诊断工具和治疗剂。
Biomolecules. 2025 Jun 1;15(6):805. doi: 10.3390/biom15060805.
2
Development of Novel ssDNA Aptamers for Detection of Receptor-Binding Domain of SARS-COV‑2.用于检测新型冠状病毒受体结合域的新型单链DNA适配体的开发
ACS Omega. 2025 Jun 3;10(23):23981-23992. doi: 10.1021/acsomega.4c03580. eCollection 2025 Jun 17.
3
Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry.

本文引用的文献

1
Targeting an evolutionarily conserved "E-L-L" motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2.靶向刺突蛋白中一个进化保守的“E-L-L”基序以鉴定一种抗SARS-CoV-2的小分子融合抑制剂。
PNAS Nexus. 2022 Oct 22;1(5):pgac198. doi: 10.1093/pnasnexus/pgac198. eCollection 2022 Nov.
2
Could a nose spray a day keep COVID away?每天喷一喷鼻子就能预防新冠吗?
Nature. 2022 Oct 31. doi: 10.1038/d41586-022-03341-z.
3
Versatile β-Catenin Is Crucial for SARS-CoV-2 Infection.多功能β-连环蛋白对新冠病毒感染至关重要。
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的复制特征以及适配体靶向刺突蛋白(S蛋白)以阻断病毒进入的优势
ACS Omega. 2025 Apr 21;10(16):15840-15851. doi: 10.1021/acsomega.4c10933. eCollection 2025 Apr 29.
4
Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications.适体和纳米抗体作为 SARS-CoV-2 诊断和治疗系统应用的新型生物探针。
Biosensors (Basel). 2024 Mar 15;14(3):146. doi: 10.3390/bios14030146.
Microbiol Spectr. 2022 Oct 26;10(5):e0167022. doi: 10.1128/spectrum.01670-22. Epub 2022 Aug 31.
4
Isolation and Characterization of Five Severe Acute Respiratory Syndrome Coronavirus 2 Strains of Different Clades and Lineages Circulating in Eastern India.印度东部流行的五种不同进化枝和谱系的严重急性呼吸综合征冠状病毒2毒株的分离与鉴定
Front Microbiol. 2022 Jun 30;13:856913. doi: 10.3389/fmicb.2022.856913. eCollection 2022.
5
Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant.奥密克戎变异株刺突蛋白受体结合域与人血管紧张素转化酶 2 的结合相互作用。
J Phys Chem Lett. 2022 May 5;13(17):3915-3921. doi: 10.1021/acs.jpclett.2c00423. Epub 2022 Apr 28.
6
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株受体结合域(RBD)与血管紧张素转换酶2(ACE2)相互作用的结构见解
Cell Res. 2022 Jun;32(6):593-595. doi: 10.1038/s41422-022-00644-8. Epub 2022 Apr 13.
7
Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.适体作为 COVID-19 大流行时代有前途的纳米治疗诊断工具。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1785. doi: 10.1002/wnan.1785. Epub 2022 Mar 3.
8
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.疫苗预防严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染和 COVID-19 疾病有效性的持续时间:系统评价和荟萃回归的结果。
Lancet. 2022 Mar 5;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. Epub 2022 Feb 23.
9
Aptamers-Diagnostic and Therapeutic Solution in SARS-CoV-2.适配子——SARS-CoV-2 的诊断和治疗解决方案。
Int J Mol Sci. 2022 Jan 26;23(3):1412. doi: 10.3390/ijms23031412.
10
Naturally occurring cancer-associated mutations disrupt oligomerization and activity of protein arginine methyltransferase 1 (PRMT1).天然发生的癌症相关突变会破坏蛋白质精氨酸甲基转移酶 1(PRMT1)的寡聚化和活性。
J Biol Chem. 2021 Nov;297(5):101336. doi: 10.1016/j.jbc.2021.101336. Epub 2021 Oct 22.